首页> 美国卫生研究院文献>other >Development validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum
【2h】

Development validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum

机译:稳定同位素稀释液相色谱电喷雾电离/选择性反应监测/质谱(SID-LC / ESI / SRM / MS)方法的开发验证和应用用于定量测定人血清中的酮-雄激素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Prostate cancer is the most frequently diagnosed form of cancer in males in the United States. The disease is androgen driven and the use of orchiectomy or chemical castration, known as androgen deprivation therapy (ADT) has been employed for the treatment of advanced prostate cancer for over 70 years. Agents such as GnRH agonists and non-steroidal androgen receptor antagonists are routinely used in the clinic, but eventually relapse occurs due to the emergence of castration-resistant prostate cancer. With the appreciation that androgen signaling still persists in these patients and the development of new therapies such as abiraterone and enzalutamide that further suppresses androgen synthesis or signaling, there is a renewed need for sensitive and specific methods to quantify androgen precursor and metabolite levels to assess drug efficacy. We describe the development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization selected reaction monitoring mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of serum keto-androgens and their sulfate and glucuronide conjugates using Girard-T oxime derivatives. The method is robust down to 0.2–4 pg on column, depending on the androgen metabolite quantified, and can also quantify dehydroepiandrosterone sulfate (DHEA-S) in only 1 μL of serum. The clinical utility of this method was demonstrated by analyzing serum androgens from patients enrolled in a clinical trial assessing combinations of pharmacological agents to maximally suppress gonadal and adrenal androgens (Targeted Androgen Pathway Suppression, TAPS clinical trial). The method was validated by correlating the results obtained with a hydroxylamine derivatization procedure coupled with tandem mass spectrometry using selected reaction monitoring that was conducted in an independent laboratory.
机译:前列腺癌是美国男性中最常被诊断的癌症形式。该疾病是雄激素驱动的,使用睾丸切除术或化学去势疗法(称为雄激素剥夺疗法(ADT))已用于治疗晚期前列腺癌已有70多年的历史了。临床上常规使用GnRH激动剂和非甾体雄激素受体拮抗剂等药物,但由于去势抵抗性前列腺癌的出现最终导致复发。随着对这些患者中雄激素信号转导仍然持续存在以及新疗法(例如阿比特龙和enzalutamide)的发展进一步抑制雄激素合成或信号转导的认识,对灵敏且特定的方法进行了新的需求,以量化雄激素前体和代谢产物水平来评估药物功效。我们描述了稳定同位素稀释液相色谱电喷雾电离选择反应监测质谱(SID-LC / ESI / SRM / MS)方法的开发,验证和应用,该方法用于定量使用Girard-K的血清酮-雄激素及其硫酸盐和葡萄糖醛酸偶联物。肟衍生物。该方法在色谱柱上的灵敏度低至0.2–4 pg,这取决于所定量的雄激素代谢物,而且还可以仅对1μL血清中的硫酸脱氢表雄酮硫酸盐(DHEA-S)进行定量。通过分析来自参加临床试验的患者的血清雄激素来评估该方法的临床实用性,该患者评估了可最大程度抑制性腺和肾上腺雄激素的药物组合(靶向雄激素途径抑制,TAPS临床试验)。通过在独立实验室中进行的选定反应监测,将羟胺衍生化程序与串联质谱联用获得的结果进行关联,从而验证了该方法的有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号